Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) introduced these days that it has introduced Sevelamer Carbonate Capsules, 800 mg, a healing identical generic model of Renvela® (sevelamer carbonate) Capsules, licensed by way of the U.S. Meals and Drug Management (USFDA).
“We’re very happy to carry Sevelamer Carbonate Capsules to marketplace at the moment,” says Alok Sonig, Govt Vice President and Head of the North The us Generics industry at Dr. Reddy’s. “This release represents Dr. Reddy’s experience and dedication to offer reasonably priced choices for advanced, limited-competition merchandise to marketplace.” That is the Corporate’s 8th general and fourth limited-competition release this fiscal yr.
The Renvela® emblem and generic had U.S. gross sales of roughly $1.88 billion MAT for the latest one year finishing in July 2017 consistent with IMS Well being.
Dr. Reddy’s Sevelamer Carbonate Capsules, 800 mg are to be had within the bottle depend measurement of 270 pills.
Renvela® is a hallmark of Genzyme Company